
Opinion|Videos|October 13, 2023
BREAKWATER Study: Encorafenib, Cetuximab, and Chemotherapy for BRAF-Mutant mCRC
Christina Wu, MB, BCh, MD, shares data from the phase 3 BREAKWATER trial, which assesses first-line targeted treatment strategies for patients with BRAF V600E-mutant metastatic colorectal cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-Edoterotide Handed CRL by FDA For GEP-NETs Treatment
2
DESTINY Trials May Reshape HER2-Positive Breast Cancer Care With T-DXd
3
BI-1808 Earns FDA Fast Track Status for Advanced Ovarian Cancer
4
Divesiran Shows Clinical Responses in Phase 2 Polycythemia Vera Trial
5























































